Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237.
Yaman Tayyar, Ryan Shiels, Andrew C Bulmer, Alfred K Lam, Daniel Clarke, Adi Idris, Nigel A McMillan
PLoS One | Published : 2019
Human papilloma virus (HPV) is the main culprit in cervical cancers. Although the HPV vaccine is now available, the slow and gradual process for HPV cancers to form means little will change, even for vaccinated individuals. This warrants the development of new therapeutic strategies in both the newly diagnosed and recurrent patients. We have previously shown that Alisertib (MLN8237), an Aurora A kinase inhibitor, potently and selectively kills HPV-positive cervical cancer cells. However, Alisertib is known for its unfavorable side effects when administered systemically. A targeted delivery approach is therefore warranted. The topical delivery of drugs to the cervix for the treatment of cervi..View full abstract